Lupin Q4 result preview: Revenue likely to rise 7%, EBITDA 85%

Lupin Q4 result preview: Pharmaceutical company Lupin is likely to report a 7 per cent growth in revenue to Rs 4,163 crore year-on-year (YoY) for Q4FY2023, according to Zee Business Research.

The chemical company’s profit after tax (PAT) is expected at Rs 167 crore compared to a loss of Rs 512 crore reported in the year-ago period. The company is likely to report adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) at Rs 495 crore against Rs 268 crore in the previous quarter. On a YoY basis, EBITDA may increase by 85 per cent.

The company's margin — a key measure of profitability for a business — is likely to increase by 500 basis points to 12 per cent from 7 per cent YoY. Margins will benefit from the fall in raw material prices according to the report.

According to Zee Business report, US sales are likely to grow by 6 per cent and are expected to be around $175 million but could decline quarter-on-quarter (QoQ). Meanwhile, domestic business can grow by 6 per cent.

On Monday, May 8, 2023, at closing, shares of Lupin traded over 4 per cent higher on BSE at Rs 733.85 apiece, and on NSE, the stock traded at Rs 732.95 per share. Lupin shares have rose over 5 per cent in value in the past six months, a period in which headline indices Nifty50 rose over 1 per cent each.

About Lupin

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

Catch the latest stock market updates here. For more news on sports, politics follow Zee Business https://www.zeebiz.com